STOCK TITAN

[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini filed Amendment No. 8 to their Schedule 13D on Royalty Pharma plc, updating their ownership and corporate details. As of June 12, 2026, they may be deemed to beneficially own 21,366,927 Class A shares, representing 4.8% of the outstanding class based on 443,274,104 shares. The amendment notes that they are no longer deemed beneficial owners of more than five percent of Royalty Pharma’s Class A shares and states this is their final amendment and exit filing. The filing also records the trust and fund structure through which the shares are held and disclaims beneficial ownership by various board members and beneficiaries.

Positive

  • None.

Negative

  • None.

Insights

Major Royalty Pharma holder reports ownership down to 4.8%, exiting 13D status.

Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini report beneficial ownership of 21,366,927 Royalty Pharma Class A shares, or 4.8% of the class, through the MGG Strategic and GG Strategic sub-funds and related trusts.

The filing states that, as of June 12, 2026, they are no longer deemed beneficial owners of more than five percent, making this a final, “exit” amendment to their Schedule 13D. Board members, trust beneficiaries, and the trustee all formally disclaim beneficial ownership of the shares.

For investors, this moves the group from large shareholder (above five percent) into a sub‑5% position. Future company filings may clarify any further changes in Royalty Pharma’s shareholder base or additional transactions by these related entities.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





G7709Q104

(CUSIP Number)
Juan Francisco Mendez, Esq.
Simpson Thacher & Bartlett LLP, 425 Lexington Avenue
New York, NY, 10017
(212) 455-2000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
06/12/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Butterfield Fiduciary Administrators Trust Company Limited
Signature:/s/ Sylvia Miller
Name/Title:Sylvia Miller, Director
Date:06/16/2026
Signature:/s/ Alison Wyser
Name/Title:Alison Wyser, Director
Date:06/16/2026
Severgnini Achille G.
Signature:/s/ Achille G. Severgnini
Name/Title:Achille G. Severgnini
Date:06/16/2026